Quick Answer
FibroBiologics, Inc. reported Stockholders Equity of $6.16 million for the year ending 2025.
- FibroBiologics, Inc. showed an increase of +125.1% in Stockholders Equity from 2024 to 2025.
- This data is from FibroBiologics, Inc.'s annual report (Form 10-K), filed with the SEC on February 24, 2026.
- XBRL data for this metric is available from 2021 to 2025 (5 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2023: $639.0 thousand | Q2 2023: $11.35 million | Q3 2023: $10.54 million | Q1 2024: -$3.86 million | Q2 2024: -$2.39 million | Q3 2024: $2.74 million | Q1 2025: $2.35 million | Q2 2025: $860.0 thousand | Q3 2025: $125.0 thousand.
- Over the full 5 years of available data (2021 to 2025), FibroBiologics, Inc.'s Stockholders Equity has grown by 577.2%.
- Historical annual values: Fiscal year 2025: $6.16 million | Fiscal year 2024: $2.74 million | Fiscal year 2023: $1.25 million | Fiscal year 2022: -$4.00 million | Fiscal year 2021: -$1.29 million.
- Data sourced from SEC EDGAR public filings as of August 7, 2026.
Last verified: